Mert Tokcan,Julian Hoevelmann,Philipp Markwirth et al.
Mert Tokcan et al.
Impact of misclassification bias on interpretation of finerenone efficacy in chronic obstructive pulmonary disease and heart failure with mildly reduced or preserved ejection fraction: A critical appraisal of the FINEARTS-HF subanalysis [0.03%]
误分类偏倚对芬戈莫德在慢性阻塞性肺疾病和射血分数轻度降低或保留的心力衰竭疗效解读的影响：对FINEARTS-HF亚组分析的批判性评价
Yang Zhang,Fanwu Chi,Ren Zhu et al.
Yang Zhang et al.
Contemporary medical therapy for heart failure across the ejection fraction spectrum: The OPTIPHARM-HF registry [0.03%]
射血分数全程的心力衰竭当代治疗现状——OPTIPHARM-HF注册研究
Riccardo M Inciardi,Maurizio Volterrani,Gianluigi Savarese et al.
Riccardo M Inciardi et al.
Aims: Despite guideline recommendations, guideline-directed medical therapy (GDMT) remains underused and underdosed in patients with heart failure (HF) across the ejection fraction (EF) spectrum. The aim of this study was...
Pharmacologic pitfalls in heart failure: A guide to drugs that may cause or exacerbate heart failure. A European Journal of Heart Failure expert consensus document [0.03%]
心力衰竭的药物陷阱：可能导致或加重心力衰竭的药物指南——欧洲心力衰竭杂志专家共识文件
Amr Abdin,Johann Bauersachs,Magdy Abdelhamid et al.
Amr Abdin et al.
Heart failure (HF) exerts a global health burden, often complicated by polypharmacy due to the frequent coexistence of cardiovascular and non-cardiovascular comorbidities. While guideline-directed medical therapy and devices have significan...
Combination diuretic therapy in acute heart failure: A systematic review and meta-analysis [0.03%]
急性心力衰竭合并用利尿剂治疗的系统性评价和荟萃分析
Francesco Fioretti,Angelica Praderio,Savina Nodari et al.
Francesco Fioretti et al.
Aims: Current guideline recommendation to use escalating doses of loop diuretics in acute heart failure (AHF) is limited by worsening renal function and by diuretic resistance. There is an unmet need for novel therapeutic...
Why healthcare providers' adherence to guideline-directed medical therapy is only half the battle [0.03%]
为何医疗提供者遵循指导医学治疗只能算打赢了半场仗
Martin Schulz,Felix Mahfoud,Ulrich Laufs
Martin Schulz
Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis [0.03%]
口服塔拉迷辛治疗野生型甲状腺素转运蛋白心肌病的临床表现和预后
Aldostefano Porcari,Paolo Milani,Simone Longhi et al.
Aldostefano Porcari et al.
Aims: Tafamidis reshaped the treatment paradigm in transthyretin amyloid cardiomyopathy (ATTR-CM) based on a phase-3 randomized controlled trial, but real-world data on its use remain limited. This study aimed to assess i...
Pharmacological treatment for patients with obesity and heart failure: Focus on glucagon-like peptide-1 receptor agonists. European Journal of Heart Failure expert consensus document [0.03%]
肥胖合并心力衰竭患者的药物治疗：聚焦肠促胰素类药物——欧洲心力衰竭专家共识文件
Luca Monzo,Gianluigi Savarese,Wilfried Mullens et al.
Luca Monzo et al.
There is growing clinical interest in strategies for improving clinical outcomes in patients with heart failure (HF) and obesity. The development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and of the dual glucose-dependent ins...
Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme [0.03%]
司美格鲁肽在肥胖相关射血分数保留型心力衰竭各年龄段患者中的疗效：STEP-HFpEF研究结果
Ambarish Pandey,Michael Moroney,Subodh Verma et al.
Ambarish Pandey et al.
Background: The prevalence of heart failure with preserved ejection fraction (HFpEF) increases with age, and older adults with HFpEF have worse physical function, quality of life, and clinical outcomes. Semaglutide demons...
Glucagon-like peptide-1 receptor agonists reduce atrial fibrillation among patients with heart failure with preserved and mildly reduced ejection fraction - a meta-analysis of randomized controlled trials [0.03%]
glucagon-like peptide-1受体激动剂可降低心力衰竭伴左室射血分数保留或轻度降低患者的房颤发生率——一项随机对照试验的meta分析
Rohanti Ravikulan,Sanjay Chavali,James E Gunton et al.
Rohanti Ravikulan et al.
Aims: Atrial fibrillation (AF) is more prevalent in heart failure with preserved ejection fraction (HFpEF) than in other heart failure phenotypes and contributes to worse clinical outcomes. Despite structural and metaboli...